Compare NMG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | DCTH |
|---|---|---|
| Founded | 2011 | 1988 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.7M | 398.7M |
| IPO Year | 2015 | 2015 |
| Metric | NMG | DCTH |
|---|---|---|
| Price | $1.30 | $12.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $5.75 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 520.0K | 332.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 107.53 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $8.12 |
| 52 Week High | $6.06 | $13.74 |
| Indicator | NMG | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 56.62 |
| Support Level | $1.26 | $9.98 |
| Resistance Level | $1.67 | $13.74 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 18.33 | 74.30 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.